Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions

被引:120
作者
Dominiak, Agnieszka [1 ,2 ]
Chelstowska, Beata [3 ]
Olejarz, Wioletta [1 ,2 ]
Nowicka, Grazyna [1 ,2 ]
机构
[1] Med Univ Warsaw, Fac Pharm, Dept Biochem & Pharmacogen, PL-02097 Warsaw, Poland
[2] Med Univ Warsaw, Ctr Preclin Res, PL-02097 Warsaw, Poland
[3] Mil Inst Med, Dept Internal Med & Hematol, Lab Hematol & Flow Cytometry, PL-04140 Warsaw, Poland
关键词
tumor microenvironment; communication in cancer; therapeutic target; oncology therapy; JUNCTIONAL INTERCELLULAR COMMUNICATION; TUNNELING NANOTUBE FORMATION; EPIDERMAL-GROWTH-FACTOR; TUMOR-TREATING FIELDS; EXTRACELLULAR VESICLES; LY2157299; MONOHYDRATE; ANTICANCER DRUGS; TIGHT JUNCTIONS; DOWN-REGULATION; GASTRIC-CANCER;
D O I
10.3390/cancers12051232
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tumor microenvironment (TME) is a complex system composed of multiple cells, such as non-cancerous fibroblasts, adipocytes, immune and vascular cells, as well as signal molecules and mediators. Tumor cells recruit and reprogram other cells to produce factors that maintain tumor growth. Communication between cancerous and surrounding cells is a two-way process and engages a diverse range of mechanisms that, in consequence, can lead to rapid proliferation, metastasis, and drug resistance, or can serve as a tumors-suppressor, e.g., through tumor-immune cell interaction. Cross-talk within the cancer microenvironment can be direct by cell-to-cell contact via adhesion molecules, electrical coupling, and passage through gap junctions, or indirect through classical paracrine signaling by cytokines, growth factors, and extracellular vesicles. Therapeutic approaches for modulation of cell-cell communication may be a promising strategy to combat tumors. In particular, integrative approaches targeting tumor communication in combination with conventional chemotherapy seem reasonable. Currently, special attention is paid to suppressing the formation of open-ended channels as well as blocking exosome production or ablating their cargos. However, many aspects of cell-to-cell communication have yet to be clarified, and, in particular, more work is needed in regard to mechanisms of bidirectional signal transfer. Finally, it seems that some interactions in TEM can be not only cancer-specific, but also patient-specific, and their recognition would help to predict patient response to therapy.
引用
收藏
页数:24
相关论文
共 190 条
[21]   Juxtacrine cell signaling molecules [J].
Bosenberg, Marcus W. ;
Massague, Joan .
CURRENT OPINION IN CELL BIOLOGY, 1993, 5 (05) :832-838
[22]   A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors [J].
Britten, Carolyn D. ;
Garrett-Mayer, Elizabeth ;
Chin, Steven H. ;
Shirai, Keisuke ;
Ogretmen, Besim ;
Bentz, Tricia A. ;
Brisendine, Alan ;
Anderton, Kate ;
Cusack, Susan L. ;
Maines, Lynn W. ;
Zhuang, Yan ;
Smith, Charles D. ;
Thomas, Melanie B. .
CLINICAL CANCER RESEARCH, 2017, 23 (16) :4642-4650
[23]   Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor [J].
Buchanan, FG ;
Wang, DZ ;
Bargiacchi, F ;
DuBois, RN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (37) :35451-35457
[24]   Tumor-associated stromal cells as key contributors to the tumor microenvironment [J].
Bussard, Karen M. ;
Mutkus, Lysette ;
Stumpf, Kristina ;
Gomez-Manzano, Candelaria ;
Marini, Frank C. .
BREAST CANCER RESEARCH, 2016, 18
[25]   VEGF as a key mediator of angiogenesis in cancer [J].
Carmeliet, P .
ONCOLOGY, 2005, 69 :4-10
[26]   Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression [J].
Chang, Chih-Hao ;
Qiu, Jing ;
O'Sullivan, David ;
Buck, Michael D. ;
Noguchi, Takuro ;
Curtis, Jonathan D. ;
Chen, Qiongyu ;
Gindin, Mariel ;
Gubin, Matthew M. ;
van der Windt, Gerritje J. W. ;
Tonc, Elena ;
Schreiber, Robert D. ;
Pearce, Edward J. ;
Pearce, Erika L. .
CELL, 2015, 162 (06) :1229-1241
[27]   Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression [J].
Chang, SH ;
Liu, CH ;
Conway, R ;
Han, DK ;
Nithipatikom, K ;
Trifan, OC ;
Lane, TF ;
Hla, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (02) :591-596
[28]   Vandetanib for the Treatment of Medullary Thyroid Cancer [J].
Chau, Nicole G. ;
Haddad, Robert I. .
CLINICAL CANCER RESEARCH, 2013, 19 (03) :524-529
[29]   Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression [J].
Chen, Jing-Yi ;
Li, Chien-Feng ;
Kuo, Cheng-Chin ;
Tsai, Kelvin K. ;
Hou, Ming-Feng ;
Hung, Wen-Chun .
BREAST CANCER RESEARCH, 2014, 16 (04)
[30]   A comprehensive overview of exosomes in ovarian cancer: emerging biomarkers and therapeutic strategies [J].
Cheng, Lin ;
Wu, Shuying ;
Zhang, Kun ;
Qing, Yun'an ;
Xu, Tianmin .
JOURNAL OF OVARIAN RESEARCH, 2017, 10